

Neglected Parasitic Infections: What Family Physicians Need to Know—A CDC Update

Paul T. Cantey, MD, MPH; Susan P. Montgomery, DVM, MPH; and Anne Straily, DVM, MPH
Centers for Disease Control and Prevention, Atlanta, Georgia

Chagas disease, cysticercosis, and toxoplasmosis affect millions of people in the United States and are considered neglected parasitic diseases. Few resources are devoted to their surveillance, prevention, and treatment. Chagas disease, transmitted by kissing bugs, primarily affects people who have lived in Mexico, Central America, and South America, and it can cause heart disease and death if not treated. Chagas disease is diagnosed by detecting the parasite in blood or by serology, depending on the phase of disease. Antiparasitic treatment is indicated for most patients with acute disease. Treatment for chronic disease is recommended for people younger than 18 years and generally recommended for adults younger than 50 years. Treatment decisions should be individualized for all other patients. Cysticercosis can manifest in muscles, the eyes, and most critically in the brain (neurocysticercosis). Neurocysticercosis accounts for 2.1% of all emergency department visits for seizures in the United States. Diagnosing neurocysticercosis involves serology and neuroimaging. Treatment includes symptom control and antiparasitic therapy. Toxoplasmosis is estimated to affect 11% of people older than six years in the United States. It can be acquired by ingesting food or water that has been contaminated by cat feces; it can also be acquired by eating undercooked, contaminated meat. *Toxoplasma* infection is usually asymptomatic; however, people who are immunosuppressed can develop more severe neurologic symptoms. Congenital infection can result in miscarriage or adverse fetal effects. Diagnosis is made with serologic testing, polymerase chain reaction testing, or parasite detection in tissue or fluid specimens. Treatment is recommended for people who are immunosuppressed, pregnant patients with recently acquired infection, and people who are immunocompetent with visceral disease or severe symptoms. (*Am Fam Physician*. 2021;104(3):277-287. Copyright © 2021 American Academy of Family Physicians.)

Neglected parasitic infections designated by the Centers for Disease Control and Prevention (CDC) include Chagas disease, cysticercosis, toxoplasmosis, toxocariasis, and trichomoniasis.¹ These parasitic infections have been prioritized based on the number of people infected, the potential for severe illness, and availability of treatment regimens. This article reviews three infections that are typically not emphasized in medical training—Chagas disease, cysticercosis, and toxoplasmosis. Information on the others (toxocariasis and trichomoniasis) can be found on the CDC website.¹ Despite the ability to cause severe illness, limited resources have been devoted to understanding the impact and burden of neglected parasitic infections. Family

physicians should understand the basic principles of clinical presentation, diagnosis, and treatment of these diseases. A summary of key points for each disease is presented in *Table 1*.²

Chagas Disease

Chagas disease (i.e., American trypanosomiasis) is caused by the parasite *Trypanosoma cruzi*. Transmission to humans occurs mainly through contact with triatomine insects (kissing bugs), bloodsucking insects that feed on humans and other animals. Infection occurs when an infected triatomine insect defecates after a blood meal, and the feces containing the parasite are rubbed into a bite wound or mucous membranes (*Figure 1*).³ Transmission can also occur congenitally or by blood transfusion, organ transplant, consumption of food contaminated with triatomine-infected feces, or laboratory exposure.

Chagas disease is endemic in many parts of Mexico and Central and South America, where an estimated 7 million people are infected.⁴ More than 300,000 people in the United States are

See related editorial on page 224.

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 228.

Author disclosure: No relevant financial affiliations.

TABLE 1

Key Elements for Chagas Disease, Cysticercosis, and Toxoplasmosis

Disease	Epidemiology and transmission	Clinical manifestations	Diagnosis
Chagas disease	More than 300,000 people in the United States are infected; more common in people who have lived in Mexico and Central or South America; locally acquired infection is rare Transmission is often vectorborne (kissing bugs), less commonly congenital, or via blood transfusion or organ transplant Blood donations are screened; blood donors who test positive cannot donate again	Acute infection: usually asymptomatic; when symptoms occur, they typically appear four to eight weeks after infection; and include nonspecific febrile illness and swelling around the bite site Chronic infection: 20% to 30% of people develop symptoms, including cardiac and gastrointestinal manifestations; increased risk of stroke Congenital infection: usually asymptomatic; anemia, hepatosplenomegaly, low Apgar scores, low birth weight, thrombocytopenia; rarely, meningoencephalitis, myocarditis	Acute and congenital infections: direct microscopy of peripheral or cord blood to detect parasites; polymerase chain reaction testing also available Chronic infection: no or few parasites in the blood; multiple serologic tests with varying sensitivity and specificity are available; at least two positive results on different serologic tests required for diagnosis
Cysticercosis	More common in immigrants from Central and South America, but can occur in people from other endemic areas and in people born in the United States Transmission occurs by ingesting eggs excreted in the feces of a tapeworm carrier; transmission does not occur by eating undercooked infected pork	Neurocysticercosis: may be asymptomatic; seizures are the most common manifestation; chronic meningitis, cranial nerve abnormalities, headache, and intracranial hypertension or hydrocephalus may also occur Muscular cysticerci are usually asymptomatic	Neurocysticercosis: computed tomography and magnetic resonance imaging are recommended; confirmatory serologic test recommended; number, location, and viability of cysticerci should be determined
Toxoplasmosis	Approximately 11% of people in the United States are infected; symptomatic infection is more common in people who are immunocompromised and in children with congenital infection Transmission is most often food-borne, zoonotic from cat feces, or congenital	Most people who are immunocompetent are asymptomatic; people who are immunosuppressed may develop encephalitis with confusion, fever, headache, poor coordination, or seizures; patients infected during pregnancy may have a miscarriage or a child born with signs of toxoplasmosis; ocular symptoms may include eye pain, blurred vision, or photophobia	<i>Toxoplasma</i> antibody test (specialized testing may be required to determine if the infection is acute or chronic); serologic tests may be unreliable in patients who are immunosuppressed; microscopy to detect parasite in blood, cerebrospinal fluid, or tissue; polymerase chain reaction testing also available

Adapted with permission from Woodhall D, Jones JL, Cantey PT, et al. Neglected parasitic infections: what every family physician needs to know. Am Fam Physician. 2014;89(10):804-805.

thought to be infected, most of whom acquired the disease in Latin America.⁴ However, infected triatomines have been found in many parts of the southern United States, and domestic transmission via triatomines has occurred.⁵

In the United States, it is estimated that up to 300 infants are congenitally infected with *T. cruzi* each year.⁴ Screening pregnant patients for Chagas disease is not routinely performed, but targeted testing based on their risk history is recommended (Figure 2). Blood donor screening in the United States was implemented in 2007, making the U.S. blood supply safe from the risk of transfusion-transmitted infection.

CLINICAL PRESENTATION

The acute phase lasts for weeks or months after the initial infection, and the chronic phase is lifelong in the absence of treatment. In the acute phase, clinical manifestations are often mild or absent; however, patients may have swelling around the bite site. If the inoculation site is the conjunctiva, unilateral palpebral edema may occur. In the chronic phase, most patients are asymptomatic, but 20% to 30% develop clinical manifestations that can be life-threatening.⁶ Cardiac disease, including conduction abnormalities, dilated cardiomyopathy, apical aneurysm, or heart failure, may occur. The risk of stroke is also increased.

Treatment

Infection is lifelong without treatment; people with acute or congenital infection and people who are immunocompromised with reactivated infection should be treated; people with severe renal or hepatic insufficiency should not be treated; patients should not be treated during pregnancy but should be evaluated for treatment after delivery; for chronic disease, treatment is strongly recommended in people younger than 18 years and generally recommended in people younger than 50 years who do not have severe cardiomyopathy; all others should be treated on an individual basis

Treatment options include nifurtimox (Lampit) or benznidazole

Neurocysticercosis: symptom control is the priority; decision to treat with antiparasitic drugs should be individualized; coadministration of corticosteroids may decrease inflammatory response

People with cysticercosis and close contacts should be screened for tapeworm infection

Spiramycin should be used before amniocentesis to assess fetal infection in pregnant patients who acquire the infection in the first or early second trimester; can also be used later in pregnancy if it has been demonstrated that the fetus is not infected

Combination therapy with pyrimethamine (Daraprim), sulfadiazine, and leucovorin should be used in infants with congenital infection, in pregnant patients who acquire infection in the late second or third trimester or who acquire the infection earlier and transmit it to the fetus, in patients who are immunosuppressed, and in patients who are immunocompetent with severe symptoms

Gastrointestinal manifestations include megasophagus or megacolon.

Most congenitally infected infants are asymptomatic; however, some may have low birth weight, low Apgar scores, or develop anemia, thrombocytopenia, or hepatosplenomegaly. Rarely, myocarditis or meningoencephalitis may occur.

DIAGNOSIS

Acute or congenital Chagas disease can be diagnosed by detecting parasites via direct microscopy of anticoagulated peripheral or cord blood. Polymerase chain reaction testing for *T. cruzi* DNA in blood may be used in addition to microscopy.

In the chronic phase, few or no parasites are present on microscopy; therefore, serologic testing for antibodies to *T. cruzi* is required for diagnosis. Positive results on at least two different tests are required for diagnosis because no single serologic test has sufficient sensitivity and specificity.

Patients who have lived in Mexico, Central America, or South America are at risk of chronic Chagas disease and should be tested. Because of the risk of congenital transmission and potentially shared exposure history, children born to mothers with Chagas disease should also be tested.^{4,7} Blood donors in the United States who have positive results on screening for *T. cruzi* infection cannot donate blood and are advised to consult with their physician for diagnostic workup and confirmation of infection.

Patients with newly diagnosed Chagas disease should have a physical examination to screen for end-organ involvement. Electrocardiography is important because arrhythmias are an early manifestation of Chagas heart disease and may be asymptomatic.

TREATMENT

Immediate antiparasitic treatment with benznidazole or nifurtimox (Lampit) is indicated for patients with acute disease, congenital infection, and for patients who are immunocompromised with reactivated disease.⁸ In chronic Chagas disease, treatment is strongly recommended for patients younger than 18 years and generally recommended for adults younger than 50 years who do not have advanced cardiomyopathy. For patients 50 years and older, treatment decisions should be individualized because most older patients have been infected for decades and treatment has a low chance of a cure.^{4,8}

Benznidazole is approved by the U.S. Food and Drug Administration (FDA) to treat children two to 12 years of age. Nifurtimox is FDA-approved to treat children from birth up to 18 years age, weighing at least 5 lb, 8 oz (2.5 kg). As of October 2020, both are commercially available. Both drugs can be used to treat older patients.

Treatment courses are 60 days. Adverse effects vary by drug and include rash, nausea, weight loss, and peripheral neuropathy. Patients with severe hepatic or renal insufficiency should not be treated with these medications because they

may be unable to adequately metabolize and excrete them. Patients should not be treated during pregnancy but should be evaluated after delivery; treatment should be avoided during breastfeeding.


Cysticercosis

Cysticercosis is a tissue infection with encysted larvae of the *Taenia solium* tapeworm. If an individual consumes undercooked pork infected with *T. solium* cysts, that individual can develop an

intestinal infection (i.e., taeniasis) with an adult tapeworm. It is usually asymptomatic; however, people with taeniasis shed tapeworm eggs in their feces, which can contaminate the environment or food in settings where personal hygiene practices or access to sanitation is poor. Individuals can then ingest the eggs, which migrate into tissues and develop into larval cysts called cysticerci (Figure 3).⁹

In the United States, the highest prevalence of cysticercosis is in immigrants from Central and

FIGURE 1



The transmission cycle of Chagas disease.


Reprinted from Centers for Disease Control and Prevention. Parasites - American trypanosomiasis (also known as Chagas disease). Biology. Updated February 11, 2019. Accessed May 13, 2020. <https://www.cdc.gov/parasites/chagas/biology.html>

South America. However, up to 15% of patients in a study of cysticercosis-associated deaths were not immigrants.¹⁰ Having household contact with a person who has taeniasis increases the risk of cysticercosis.

CLINICAL PRESENTATION

Cysticerci can develop in subcutaneous tissue, muscles, eyes, the brain, or the spinal cord. Symptom onset can be from months to years after the initial infection. Symptoms are usually caused by an inflammatory response to dying parasites but can also be caused by mass effects. Some patients may develop lumps under the skin.

FIGURE 2



Neurocysticercosis occurs when cysticerci invade the central nervous system. The most common clinical manifestations are seizures, occurring in 50% to 80% of symptomatic patients with parenchymal cysts, and intracranial hypertension or hydrocephalus, which occurs in 20% to 30% of symptomatic patients.¹¹ In endemic areas, up to 30% of seizures are caused by cysticercosis. In one study in the United States, 2.1% of visits to emergency departments for seizures were attributed to neurocysticercosis.¹² Other neurologic manifestations include headache, chronic meningitis, and cranial nerve abnormalities. Parenchymal disease with few cysts has a better long-term prognosis than extraparenchymal disease or infection with multiple cysts.¹³

DIAGNOSIS

Evaluation of patients with cysticercosis is designed to identify patients who may benefit from medical or surgical intervention to prevent or reduce complications.

The diagnostic evaluation of patients suspected of having neurocysticercosis is outlined in *Figure 4*. Computed tomography and magnetic resonance imaging are recommended for diagnosis and determining a treatment plan.¹⁴ Serologic testing is also recommended to confirm the diagnosis.¹⁴ An enzyme-linked immunoelectrotransfer blot assay (available through the parasitic diseases branch at the CDC and some reference laboratories) is the preferred serologic test because its sensitivity and specificity are superior to more readily available enzyme-linked immunosorbent assays.¹⁴

TREATMENT

Initial treatment of neurocysticercosis should focus on symptom control (e.g., antiepileptic drugs for seizures, dexamethasone for edema, neurosurgery for hydrocephalus) instead of immediate initiation of antiparasitic therapy.

When symptoms are controlled, antiparasitic therapy should be individualized, considering the patient's symptoms and the number, viability, and location of cysticerci.^{14,15} Antiparasitic treatment can cause a severe inflammatory reaction by killing viable cysts; corticosteroids should be used to suppress this response.¹⁶ Guidelines for the diagnosis and management of neurocysticercosis have been published.¹⁴ The treatment plan

FIGURE 3





FIGURE 4



*—Seizure and increased intracranial pressure are the most common presentations of neurocysticercosis; there may be other symptoms.

†—Additional therapy may involve albendazole (Albenza), praziquantel (Biltricide), or both; surgical intervention for ventricular lesions; corticosteroids for perilesional edema; and treatment of *Strongyloides* infection if prolonged use of corticosteroids is anticipated.

Diagnosis and management of neurocysticercosis in patients presenting with new seizures or increased intracranial pressure.

Patients with toxoplasmosis who are immunosuppressed may have severe manifestations of infection, including encephalitis, fever, headache, seizures, confusion, or ataxia. These conditions may result from a new infection or reactivation of a previous infection.²⁰

Congenital infections can also occur, but the risk of congenital transmission depends on when maternal infection is acquired, with higher rates of transmission when the infection is acquired later in pregnancy.²¹ If the infection is acquired during pregnancy or within three months of

should be developed in collaboration with an infectious disease specialist who has experience treating neurocysticercosis.

If necessary, people diagnosed with cysticercosis and their close contacts should be screened for taeniasis and be treated. Strategies to prevent cysticercosis include handwashing and washing raw vegetables and fruits before eating. People traveling to endemic areas should drink only purified or bottled water and eat only fruits and vegetables that have been cooked or that they have peeled themselves.

Toxoplasmosis

Toxoplasmosis is caused by the parasite *Toxoplasma gondii*. Approximately 11% of people in the United States who are older than six years are estimated to be infected.¹⁷ Once an individual is infected, the parasite stays in the body in an inactive state but can reactivate if they become immunosuppressed.

Cats are the definitive host for *T. gondii* and can shed oocysts in their feces for several weeks after the initial infection. Cats primarily become infected by consuming infected paratenic (transport) hosts, such as small rodents, that have become infected by consuming infective oocysts from the environment.


Humans can become infected by ingesting water or raw fruits or vegetables that have been contaminated with cat feces (Figure 5).¹⁷ Humans can also acquire *Toxoplasma* infection by eating undercooked meat from infected domesticated animals (e.g., cattle, sheep, goats) or wild animals (e.g., deer), or eating food contaminated by raw infected meat.

Transmission can also occur by blood transfusion or organ transplant. Congenital transmission occurs when a patient is newly infected with *T. gondii* during pregnancy or just before becoming pregnant.

CLINICAL PRESENTATION

Most people who are immunocompetent are asymptomatic; however, some may experience mild flulike symptoms including myalgias, or cervical or occipital lymphadenopathy, that typically resolve spontaneously over several weeks.¹⁸ A small percentage (less than 2%) of people infected with *T. gondii* after birth develop ocular disease.¹⁹

FIGURE 5



The transmission cycle of toxoplasmosis.

Reprinted from Centers for Disease Control and Prevention. Parasites - toxoplasmosis. (Toxoplasma infection). Biology. Updated November 10, 2020. Accessed May 13, 2020. <https://www.cdc.gov/parasites/toxoplasmosis/biology.html>

becoming pregnant, there is a risk of congenital transmission. However, if a patient who is immunocompetent acquires the infection earlier than three months before pregnancy, the risk of congenital transmission is essentially zero.²²


Congenital infections can result in miscarriage or an infant born with signs of toxoplasmosis (e.g., jaundice, chorioretinitis, ventriculomegaly, hydrocephalus, intracranial calcifications, macrocephaly, microcephaly, seizures).²² Some of these findings may be noted on fetal ultrasound. Congenitally infected infants are often asymptomatic at birth. Ocular disease, usually

chorioretinitis, may develop later in life, including in adulthood, in 20% to 80% of people with congenital infection. Symptoms include blurred vision, eye pain, and photophobia.

DIAGNOSIS

Diagnosis of toxoplasmosis can be achieved with serologic tests that detect *Toxoplasma* antibodies (e.g., immunoglobulin [Ig] G, IgM, IgA, IgE; Figure 6). Many commercial and clinical laboratories offer IgM and IgG testing. Polymerase chain reaction testing or direct observation of the parasite in blood, tissue, or cerebrospinal fluid is

FIGURE 6



IG = immunoglobulin.

Diagnosis and management of toxoplasmosis in people who are immunocompetent.

useful in patients who are immunosuppressed, in whom the diagnosis may be difficult to confirm with antibody tests. In patients with neurologic symptoms, multiple brain abscesses or ring enhancement may be noted on neuroimaging.

Among pregnant patients with suspected disease because of abnormal ultrasonography findings or clinical symptoms of acute infection, commercial IgM and IgG tests are useful, but only for initial testing.²² A diagnosis of acute infection should be confirmed by a reference laboratory that can conduct additional tests (e.g., avidity and agglutination tests) to determine the timing of infection because false-positive results may occur with IgM testing and because IgG may be present in acute (rather than only chronic) infections. In the United States, the Dr. Jack S. Remington Laboratory for Specialty Diagnostics serves as the toxoplasmosis reference laboratory (<https://www.sutterhealth.org/services/laboratory/toxoplasma-serology-laboratory>). To evaluate for congenital transmission to the fetus, ultrasonography and polymerase chain reaction

testing of amniotic fluid can be done as early as the 18th week of gestation.

TREATMENT

Treatment of adults who are immunocompetent is rarely warranted because symptoms usually resolve without treatment. If visceral disease is present, or symptoms are severe, pyrimethamine (Daraprim), sulfadiazine, and leucovorin may be administered for two to four weeks (*Figure 6*). People with toxoplasmosis who are immunosuppressed need continuous treatment until their immunologic state has improved.²⁰

Patients infected during the first or early second trimester of pregnancy should be treated with spiramycin to reduce the risk of transmission of toxoplasmosis to the fetus and is most effective if initiated within eight weeks of maternal seroconversion. Spiramycin can be obtained from the FDA (telephone 301-796-1400). Spiramycin treatment should be continued throughout pregnancy if there is no evidence of fetal infection.²²

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Children born to mothers with Chagas disease should be tested for congenital infection. ^{4,7}	C	Recommendation based on prevalence of Chagas disease among women of childbearing age
Computed tomography and magnetic resonance imaging are recommended for diagnosis and determination of a treatment plan for patients with neurocysticercosis. ¹⁴	C	Evidence-based clinical practice guideline
Serologic testing is also recommended to confirm the diagnosis of neurocysticercosis. Enzyme-linked immunoabsorbent assay is the preferred serologic test. ¹⁴	C	Evidence-based clinical practice guideline
Among pregnant patients with suspected toxoplasmosis because of abnormal ultrasonography findings or clinical symptoms of acute infection, commercial IgM and IgG are useful but only for initial testing. A diagnosis of acute infection should be confirmed by a reference laboratory that can conduct additional tests because false-positive results may occur with IgM testing, and IgG may sometimes be present in acute (not only chronic) infections. ²²	C	Evidence-based practice guideline

Ig = immunoglobulin.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

When there is evidence of fetal infection (confirmed by amniocentesis or suspected based on fetal ultrasonography) or when the infection is acquired during the late second or third trimester, combination therapy consisting of pyrimethamine, sulfadiazine, and leucovorin is usually administered. Infants with congenitally acquired infection should also receive the pyrimethamine, sulfadiazine, and leucovorin combination.²²

PREVENTION

Patients at risk of severe outcomes from toxoplasmosis (e.g., immunocompromised, pregnant) should be counseled on how to decrease the risk of acquiring infections. Strategies related to food include thoroughly cooking meats and peeling or washing fruits and vegetables before eating; washing food preparation materials after contact with raw meat or unwashed fruits or vegetables; avoiding drinking unpasteurized milk and untreated or contaminated water; and avoiding eating raw or undercooked shellfish (e.g., oysters, mussels, clams) because they may be contaminated with oocysts washed into seawater.²³

Patients should wear gloves when gardening or during any contact with soil or sand, wash hands

thoroughly with soap and water after contact with soil or sand, and keep sandboxes covered when not in use.

Strategies related to cats include preventing cats from hunting and changing litter boxes daily. However, pregnant patients and people who are immunosuppressed should avoid cleaning litter boxes if possible. When people who are immunosuppressed must perform this task, they should wear disposable gloves and wash their hands thoroughly with soap and water afterward. These patients should also avoid adopting stray cats, especially kittens.

This article updates a previous article on this subject by Woodhall, et al.²

Data Sources: A PubMed search was completed using the key terms epidemiology, diagnosis, treatment, and United States for each of the following diseases: Chagas disease, cysticercosis, and toxoplasmosis. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. The CDC website was also reviewed. Search dates: March 1, 2020 and April 8, 2021.

The findings and conclusions expressed in this article are those of the authors and do not necessarily represent the views of the CDC.

Further information about Chagas disease, toxocariasis, cysticercosis, and toxoplasmosis is available

through the CDC website (<http://www.cdc.gov/parasites/npi.html>). Resources include fact sheets for patients and physicians, continuing medical education courses, and audio podcasts for each disease. Consultation with experts and information about diagnostic testing and investigational drugs are available through the Parasitic Diseases Branch Public Inquiries desk (telephone: 404-718-4745; email: parasites@cdc.gov).

The Authors

PAUL T. CANTEY, MD, MPH, is a medical officer in the Division of Parasitic Diseases and Malaria at the Centers for Disease Control and Prevention, Atlanta, Ga.

SUSAN P. MONTGOMERY, DVM, MPH, is a veterinary medical officer in the Division of Parasitic Diseases and Malaria at the Centers for Disease Control and Prevention.

ANNE STRAILY, DVM, MPH, is a veterinary medical officer in the Division of Parasitic Diseases and Malaria at the Centers for Disease Control and Prevention.

Address correspondence to Paul T. Canney, MD, MPH, 1600 Clifton Rd., MS H24-3, Atlanta, GA 30329 (email: gdn9@cdc.gov). Reprints are not available from the authors.

References

1. Centers for Disease Control and Prevention. Parasites – parasitic infections in the United States. November 20, 2020. Accessed February 22, 2021. <https://www.cdc.gov/parasites/npi/index.html>
2. Woodhall D, Jones JL, Canney PT, et al. Neglected parasitic infections: what every family physician needs to know. *Am Fam Physician*. 2014;89(10):803-811. Accessed February 22, 2021. <https://www.aafp.org/afp/2014/0515/p803.html>
3. Centers for Disease Control and Prevention. Parasites – American trypanosomiasis (also known as Chagas disease). Biology. Updated February 11, 2019. Accessed May 13, 2020. <https://www.cdc.gov/parasites/chagas/biology.html>
4. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. *Clin Infect Dis*. 2009; 49(5):e52-e54.
5. Bern C, Messenger LA, Whitman JD, et al. Chagas disease in the United States: a public health approach. *Clin Microbiol Rev*. 2019;33(1):e00023-19.
6. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. *Lancet*. 2010;375(9723):1388-1402.
7. Centers for Disease Control and Prevention. Congenital Chagas disease. April 8, 2019. Accessed May 5, 2021. https://www.cdc.gov/parasites/chagas/health_professionals/congenital_chagas.html
8. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. *JAMA*. 2007;298(18):2171-2181.
9. Centers for Disease Control and Prevention. Parasites – cysticercosis. Biology. Updated September 22, 2020. Accessed May 13, 2020. <https://www.cdc.gov/parasites/cysticercosis/biology.html>
10. Sorvillo FJ, DeGiorgio C, Waterman SH. Deaths from cysticercosis, United States. *Emerg Infect Dis*. 2007;13(2):230-235.
11. Garcia HH, Gonzalez AE, Evans CAW, et al.; Cysticercosis Working Group in Peru. *Taenia solium* cysticercosis. *Lancet*. 2003;362(9383):547-556.
12. Ong S, Talan DA, Moran GJ, et al.; EMERGEID NET Study Group. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. *Emerg Infect Dis*. 2002;8(6):608-613.
13. Nash TE, O'Connell EM, Hammoud DA, et al. Natural history of treated subarachnoid neurocysticercosis. *Am J Trop Med Hyg*. 2020;102(1):78-89.
14. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America and the American Society of Tropical Medicine and Hygiene. *Clin Infect Dis*. 2018;66(8):e49-e75.
15. Garcia HH, Gonzales I, Lescano AG, et al.; Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. *Lancet Infect Dis*. 2014;14(8):687-695.
16. Garcia HH, Gonzales I, Lescano AG, et al.; Cysticercosis Working Group in Peru. Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. *Epilepsia*. 2014;55(9):1452-1459.
17. Centers for Disease Control and Prevention. Parasites – toxoplasmosis (*Toxoplasma* infection). Biology. November 10, 2020. Accessed May 13, 2020. <https://www.cdc.gov/parasites/toxoplasmosis/biology.html>
18. Jones JL, Kruszon-Moran D, Wilson M. *Toxoplasma gondii* infection in the United States, 1999-2000. *Emerg Infect Dis*. 2003;9(11):1371-1374.
19. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. *Am J Ophthalmol*. 2003;136(6):973-988.
20. ClinicalInfoHIV.gov. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. *Toxoplasma gondii* encephalitis. Updated July 25, 2017. Accessed May 13, 2020. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/toxoplasma-gondii-encephalitis?view=full>
21. Dunn D, Wallon M, Peyron F, et al. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. *Lancet*. 1999;353(9167):1829-1833.
22. Maldonado YA, Read JS; Committee on Infectious Diseases. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. *Pediatrics*. 2017;139(2):e20163860.
23. Jones JL, Dargelas V, Roberts J, et al. Risk factors for *Toxoplasma gondii* infection in the United States. *Clin Infect Dis*. 2009;49(6):878-884.